

1  
2  
3  
4

## SEQUENCE LISTING

5

## (1) GENERAL INFORMATION:

Does not comply  
- Send a notice -

6

(i) APPLICANT: Opperman, Hermann  
Ozkaynak, Engin  
Rueger, David C.  
Kuberasampath, Thangavel  
(ii) TITLE OF INVENTION: Osteogenic Proteins  
(iii) NUMBER OF SEQUENCES: 11  
(iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Testa Hurwitz & Thibeault  
(B) STREET: 53 State Street  
(C) CITY: Boston  
(D) STATE: Massachusetts  
(E) COUNTRY: U.S.A.  
(F) ZIP: 02109

21

(v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage  
(B) COMPUTER: IBM XT  
(C) OPERATING SYSTEM: DOS 3.30  
(D) SOFTWARE: ASC II

26

(vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER: US 07/599,543  
(B) FILING DATE: 18-Oct-90

29

(vii) ~~PRIOR APPLICATION DATA:~~ *insert*  
(A) APPLICATION NUMBER: US 569,920  
(B) FILING DATE: 20-Aug-90  
(C) APPLICATION NUMBER: US 315,342  
(D) FILING DATE: 23-Feb-89  
(E) APPLICATION NUMBER: US 422,699  
(F) FILING DATE: 17-Oct-89

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

(C) CLASSIFICATION:

54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70

71 (2) INFORMATION FOR SEQ ID NO:1:  
72 (i) SEQUENCE CHARACTERISTICS:  
73 (A) LENGTH: 139 amino acids  
74 (B) TYPE: amino acid  
75 (D) TOPOLOGY: linear  
76 (ii) MOLECULE TYPE: protein  
77 (ix) FEATURE:  
78 (A) NAME: mOP2 (mature)  
79 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
80

81 Ala Ala Arg Pro Leu Lys Arg Arg Gln  
82 1 5  
83 Pro Lys Lys Thr Asn Glu Leu Pro His  
84 10 15  
85 Pro Asn Lys Leu Pro Gly Ile Phe Asp  
86 20 25  
87 Asp Gly His Gly Ser Arg Gly Arg Glu  
88 30 35  
89 Val Cys Arg Arg His Glu Leu Tyr Val  
90 40 45  
91 Arg Phe Arg Asp Leu Gly Trp Leu Asp  
92 50  
93 Trp Val Ile Ala Pro Gln Gly Tyr Ser  
94 55 60  
95 Ala Tyr Tyr Cys Glu Gly Glu Cys Ala  
96 65 70  
97 Phe Pro Leu Asp Ser Cys Met Asn Ala  
98 75 80  
99 Thr Asn His Ala Ile Leu Gln Ser Leu  
100 85 90  
101 Val His Leu Met Lys Pro Asp Val Val  
102 95  
103 Pro Lys Ala Cys Cys Ala Pro Thr Lys  
104 100 105  
105 Leu Ser Ala Thr Ser Val Leu Tyr Tyr  
106 110 115

107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137 Asp Ser Ser Asn Asn Val Ile Leu Arg  
138 120 125  
139 Lys His Arg Asn Met Val Val Lys Ala  
140 130 135  
141 Cys Gly Cys His  
142  
143  
144 (2) INFORMATION FOR SEQ ID NO:2:  
145 (i) SEQUENCE CHARACTERISTICS:  
146 (A) LENGTH: 1930 base pairs  
147 (B) TYPE: nucleic acid  
148 (C) STRANDEDNESS: single  
149 (D) TOPOLOGY: linear  
150 (ii) MOLECULE TYPE: cDNA  
151 (iii) HYPOTHETICAL: no  
152 (iv) ANTI-SENSE: no  
153 (vi) ORIGINAL SOURCE:  
154 (A) ORGANISM: mouse  
155 (F) TISSUE TYPE: embryo  
156 (ix) FEATURE:  
157 (A) NAME: mOP2  
158 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  
159

## Patent Application US/07/599,543B

160 GGAATTCCGC TGCCAGGCAC AGGTGCGCCG TCTGGTCCTC 40  
161 CCCGTCTGGC GTCAGCCGAG CCCGACCAGC TACCAAGTGGA 80  
162 TGCAGCCGG CTGAAAGTCC GAG ATG GCT ATG CGT 115  
163 Met Ala Met Arg  
164 1  
165 CCC GGG CCA CTC TGG CTA TTG GGC CTT GCT CTG 148  
166 Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu  
167 5 10 15  
168 TGC GCG CTG GGA GGC GGC CAC GGT CCC GGT CCC 181  
169 Cys Ala Leu Gly Gly His Gly Pro Gly Pro  
170 20 25  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202 CCG CAC ACC TGT CCC CAG CGT CGC CTG GGA GCG 214  
203 Pro His Thr Cys Pro Gln Arg Arg Leu Gly Ala  
204 30 35  
205 CGC GAC CGG GAC ATG CAG CGT GAA ATC CTG CCG 247  
206 Arg Asp Arg Asp Met Gln Arg Glu Ile Leu Pro  
207 40 45  
208 GTG CTC GGG CTA CCG GGA CGC CCC GAC CCC GTG 280  
209 Val Leu Gly Leu Pro Gly Arg Pro Asp Pro Val  
210 50 55  
211 CAC AAC CCG CCG CTG CCC GGC ACG CAG CGT GCG 313  
212 His Asn Pro Pro Leu Pro Gly Thr Gln Arg Ala

## Patent Application US/07/599,543B

213 60 65 70  
214 CCC CTC TTC ATG TTG GAC CTA TAC CAC GCC ATG 346  
215 Pro Leu Phe Met Leu Asp Leu Tyr His Ala Met  
216 75 80  
217 ACC GAT GAC GAC GAC GCC GGG CCA CCA CAG GCT 379  
218 Thr Asp Asp Asp Asp Gly Gly Pro Pro Gln Ala  
219 85 90  
220 CAC TTA GGC CGT GCC GAC CTG GTC ATG AGC TTC 412  
221 His Leu Gly Arg Ala Asp Leu Val Met Ser Phe  
222 95 100  
223 GTC AAC ATG GTG GAA CGC GAC CGT ACC CTG GGC 445  
224 Val Asn Met Val Glu Arg Asp Arg Thr Leu Gly  
225 105 110  
226 TAC CAG GAG CCA CAC TGG AAG GAA TTC CAC TTT 478  
227 Tyr Gln Glu Pro His Trp Lys Glu Phe His Phe  
228 115 120 125  
229 GAC CTA ACC CAG ATC CCT GCT GGG GAG GCT GTC 511  
230 Asp Leu Thr Gln Ile Pro Ala Gly Glu Ala Val  
231 130 135  
232 ACA GCT GCT GAG TTC CGG ATC TAC AAA GAA CCC 544  
233 Thr Ala Ala Glu Phe Arg Ile Tyr Lys Glu Pro  
234 140 145  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265

## Patent Application US/07/599,543B

266  
267 AGC ACC CAC CCG CTC AAC ACA ACC CTC CAC ATC 577  
268 Ser Thr His Pro Leu Asn Thr Thr Leu His Ile  
269 150 155  
270 AGC ATG TTC GAA GTG GTC CAA GAG CAC TCC AAC 610  
271 Ser Met Phe Glu Val Val Gln Glu His Ser Asn  
272 160 165  
273 AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG 643  
274 Arg Glu Ser Asp Leu Phe Leu Asp Leu Gln  
275 170 175 180  
276 ACG CTC CGA TCT GGG GAC GAG GGC TGG CTG GTG 676  
277 Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu Val  
278 185 190  
279 CTG GAC ATC ACA GCA GCC AGT GAC CGA TGG CTG 709  
280 Leu Asp Ile Thr Ala Ala Ser Asp Arg Trp Leu  
281 195 200  
282 CTG AAC CAT CAC AAG GAC CTG GGA CTC CGC CTC 742  
283 Leu Asn His His Lys Asp Leu Gly Leu Arg Leu  
284 205 210  
285 TAT GTG GAA ACC GCG GAT GGG CAC AGC ATG GAT 775  
286 Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp  
287 215 220  
288 CCT GGC CTG GCT GGT CTG CTT GGA CGA CAA GCA 808  
289 Pro Gly Leu Ala Gly Leu Leu Gly Arg Gln Ala  
290 225 230 235  
291 CCA CGC TCC AGA CAG CCT TTC ATG GTA ACC TTC 841  
292 Pro Arg Ser Arg Gln Pro Phe Met Val Thr Phe  
293 240 245  
294 TTC AGG GCC AGC CAG AGT CCT GTG CGG GCC CCT 874  
295 Phe Arg Ala Ser Gln Ser Pro Val Arg Ala Pro  
296 250 255  
297 CGG GCA GCG AGA CCA CTG AAG AGG AGG CAG CCA 907  
298 Arg Ala Ala Arg Pro Leu Lys Arg Arg Gln Pro  
299 260 265  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318

319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332 AAG AAA ACG AAC GAG CTT CCG CAC CCC AAC AAA 940  
333 Lys Lys Thr Asn Glu Leu Pro His Pro Asn Lys  
334 270 275  
335 CTC CCA GGG ATC TTT GAT GAT GGC CAC GGT TCC 973  
336 Leu Pro Gly Ile Phe Asp Asp Gly His Gly Ser  
337 280 285 290  
338 CGC GGC AGA GAG GTT TGC CGC AGG CAT GAG CTC 1006  
339 Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu  
340 295 300  
341 TAC GTC AGA TTC CGT GAC CTT GGC TGG CTG GAC 1039  
342 Tyr Val Arg Phe Arg Asp Leu Gly Trp Leu Asp  
343 305 310  
344 TGG GTC ATC GCC CCC CAG GGC TAC TCT GCC TAT 1072  
345 Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr  
346 315 320  
347 TAC TGT GAG GGG GAG TGT GCT TTC CCA CTG GAC 1105  
348 Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp  
349 325 330  
350 TCC TGT ATG AAC GCC ACC AAC CAT GCC ATC TTG 1138  
351 Ser Cys Met Asn Ala Thr Asn His Ala Ile Leu  
352 335 340 345  
353 CAG TCT CTG GTG CAC CTG ATG AAG CCA GAT GTT 1171  
354 Gln Ser Leu Val His Leu Met Lys Pro Asp Val  
355 350 355  
356 GTC CCC AAG GCA TGC TGT GCA CCC ACC AAA CTG 1204  
357 Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu  
358 360 365  
359 AGT GCC ACC TCT GTG CTG TAC TAT GAC AGC AGC 1237  
360 Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser  
361 370 375  
362 AAC AAT GTC ATC CTG CGT AAA CAC CGT AAC ATG 1270  
363 Asn Asn Val Ile Leu Arg Lys His Arg Asn Met  
364 380 385  
365  
366  
367  
368  
369  
370  
371

372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397 GTG GTC AAG GCC TGT GGC TGC CAC 1294  
398 Val Val Lys Ala Cys Gly Cys His  
399 390 400  
400 TGAGGCCCG CCCAGCATCC TGCTTCTACT ACCTTACCAT 1334  
401 CTGGCCGGGC CCCCTCTCCAG AGGCAGAAAC CCTTCTATGT 1374  
402 TATCATAGCT CAGACAGGGG CAATGGGAGG CCCTTCACCT 1414  
403 CCCCTGGCCA CTTCCCTGCTA AAATTCTGGT CTTTCCCAGT 1454  
404 TCCCTCTGTCC TTCATGGGT TTCCGGGCTA TCACCCCGCC 1494  
405 CTCTCCATCC TCCTACCCCA AGCATAGACT GAATGCACAC 1534  
406 AGCATCCCAG AGCTATGCTA ACTGAGAGGT CTGGGGTCAG 1574  
407 CACTGAAGGC CCACATGAGG AAGACTGATC CTTGGCCATC 1614  
408 CTCAGCCCAC AATGGCAAAT TCTGGATGGT CTAAGAAGCC 1654  
409 CTGGAATTCT AAACTAGATG ATCTGGGCTC TCTGCACCAT 1694  
410 TCATTGTGGC AGTTGGGACA TTTTTAGGTA TAACAGACAC 1734  
411 ATACACTTAG ATCAATGCAT CGCTGTACTC CTTGAAATCA 1774  
412 GAGCTAGCTT GTTAGAAAAA GAATCAGAGC CAGGTATAGC 1814  
413 GGTGCATGTC ATTAATCCCA GCGCTAAAGA GACAGAGACA 1854  
414 GGAGAATCTC TGTGAGTTCA AGGCCACATA GAAAGAGCCT 1894  
415 GTCTCGGGAG CAGGAAAAAA AAAAAAAACG GAATTCA 1930  
416  
417  
418 (2) INFORMATION FOR SEQ ID NO:3:  
419 (i) SEQUENCE CHARACTERISTICS:  
420 (A) LENGTH: 139 amino acids  
421 (B) TYPE: amino acid  
422 (D) TOPOLOGY: linear  
423 (ii) MOLECULE TYPE: protein  
424 (ix) FEATURE:

Patent Application US/07/599,543B

425 (A) NAME: hOP2 (mature)  
426 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:  
427  
428 Ala Val Arg Pro Leu Arg Arg Arg Gln  
429 1 5  
430 Pro Lys Lys Ser Asn Glu Leu Pro Gln  
431 10 15  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464 Ala Asn Arg Leu Pro Gly Ile Phe Asp  
465 20 25  
466 Asp Val His Gly Ser His Gly Arg Gln  
467 30 35  
468 Val Cys Arg Arg His Glu Leu Tyr Val  
469 40 45  
470 Ser Phe Gln Asp Leu Gly Trp Leu Asp  
471 50  
472 Trp Val Ile Ala Pro Gln Gly Tyr Ser  
473 55 60  
474 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser  
475 65 70  
476 Phe Pro Leu Asp Ser Cys Met Asn Ala  
477 75 80

## Patent Application US/07/599,543B

478 Thr Asn His Ala Ile Leu Gln Ser Leu  
479 85 90  
480 Val His Leu Met Lys Pro Asn Ala Val  
481 95  
482 Pro Lys Ala Cys Cys Ala Pro Thr Lys  
483 100 105  
484 Leu Ser Ala Thr Ser Val Leu Tyr Tyr  
485 110 115  
486 Asp Ser Ser Asn Asn Val Ile Leu Arg  
487 120 125  
488 Lys Ala Arg Asn Met Val Val Lys Ala  
489 130 135  
490 Cys Gly Cys His  
491  
492

493 (2) INFORMATION FOR SEQ ID NO:4:  
494 (i) SEQUENCE CHARACTERISTICS:  
495 (A) LENGTH: 1956 base pairs  
496 (B) TYPE: nucleic acid  
497 (C) STRANDEDNESS: single

only 1941 are listed  
See line 797

498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529 (D) TOPOLOGY: linear  
530 (ii) MOLECULE TYPE: cDNA

## Patent Application US/07/599,543B

531 (iii) HYPOTHETICAL: no  
532 (iv) ANTI-SENSE: no  
533 (vi) ORIGINAL SOURCE:  
534 (A) ORGANISM: homo sapiens  
535 (F) TISSUE TYPE: hippocampus  
536 (ix) FEATURE:  
537 (A) NAME: hOP2  
538 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
539  
540 GGAATTCCGG CCACAGTGGC GCCGGCAGAG CAGGAGTGGC 40  
541 TGGAGGAGCT GTGGTTGGAG CAGGAGGTGG CACGGCAGGG 80  
542 CTGGAGGGCT CCCTATGGAGT GCGGGAGACG GCCCAGGAGG 120  
543 CGCTGGAGCA ACAGCTCCCA CACCGCACCA AGCGGTGGCT 160  
544 GCAGGGAGCTC GCCCCATCGCC CCTGCGCTGC TCGGACCGCG 200  
545 GCCACAGCCG GACTGGCGGG TACGGCGGGCG ACAGAGGCAT 240  
546 TGGCCGAGAG TCCCAGTCCG CAGAGTAGCC CCGGCCTCGA 280  
547 GGCAGGTGGCG TCCCGGTCCCT CTCCGTCCAG GAGCCAGGAC 320  
548 AGGTGTCGCG CGGCGGGGCT CCAGGGACCG CGCCTGAGGC 360  
549 CGGCTGCCCG CCCGTCCCCGC CCCGCCCCGC CGCCCGCCGC 400  
550 CCCGCCGAGCC CAGCCTCCTT GCCGTCGGGG CGTCCCCAGG 440  
551 CCCTGGGTGCG GCCGCGGAGC CGATGCGCGC CCGCTGAGCG 480  
552 CCCCAGCTGA GCGCCCCCGG CCTGCC ATG ACC GCG CTC 518  
553 Met Thr Ala Leu  
554 1  
555 CCC GGC CCG CTC TGG CTC CTG GGC CTG GCG CTA 551  
556 Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu  
557 5 10 15  
558 TGC GCG CTG GGC GGG GGC GGC CCC GGC CTG CGA 584  
559 Cys Ala Leu Gly Gly Gly Pro Gly Leu Arg  
560 20 25  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583

584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594 CCC CCG CCC GGC TGT CCC CAG CGA CGT CTG GGC 617  
595 Pro Pro Pro Gly Cys Pro Gly arg Arg Leu Gly  
596 30 35  
597 GCG CGC GAC CGG GAC GTG CAG CGC GAG ATC CTG 650  
598 Ala Arg Asp Arg Asp Val Gln Arg Glu Ile Leu  
599 40 45  
600 GCG GTG CTC GGG CTG CCT GGG CGG CCC CGG CCC 683  
601 Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro  
602 50 55  
603 CGC GCG CCA CCC GCC GCC TCC CGG CTG CCC GCG 716  
604 Arg Ala Pro Pro Ala Ala Ser Arg Leu Pro Ala  
605 60 65 70  
606 TCC GCG CCG CTC TTC ATG CTG GAC CTG TAC CAC 749  
607 Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr His  
608 75 80  
609 CGC ATG GCC GGC GAC GAC GAC GAG GAC GGC GCC 782  
610 Arg Met Ala Gly Asp Asp Asp Glu Asp Gly Ala  
611 85 90  
612 GCG GAG GCC CTG GGC CGC GCC GAC CTG GTC ATG 815  
613 Ala Glu Ala Leu Gly Arg Ala Asp Leu Val Met  
614 95 100  
615 AGC TTC GTT AAC ATG GTG GAG CGA GAC CGT GCC 848  
616 Ser Phe Val Asn Met Val Glu Arg Asp Arg Ala  
617 105 110  
618 CTG GGC CAC CAG GAG CCC CAT TGG AAG GAG TTC 881  
619 Leu Gly His Gln Glu Pro His Trp Lys Glu Phe  
620 115 120 125  
621 CGC TTT GAC CTG ACC CAG ATC CCG GCT GGG GAG 914  
622 Arg Phe Asp Leu Thr Gln Ile Pro Ala Gly Glu  
623 130 135  
624 GCG GTC ACA GCT GCG GAG TTC CGG ATT TAC AAG 947  
625 Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys  
626 140 145  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636

## Patent Application US/07/599,543B

637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659 GTG CCC AGC ATC CAC CTG CTC AAC AGG ACC CTC 980  
660 Val Pro Ser Ile His Leu Leu Asn Arg Thr Leu  
661 150 155  
662 CAC GTC AGC ATG TTC CAG GTG GTC CAG GAG CAG 1013  
663 His Val Ser Met Phe Gln Val Val Gln Glu Gln  
664 160 165  
665 TCC AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT 1046  
666 Ser Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp  
667 170 175 180  
668 CTT CAG ACG CTC CGA GCT GGA GAC GAG GGC TGG 1079  
669 Leu Gln Thr Leu Arg Ala Gly Asp Glu Gly Trp  
670 185 190  
671 CTG GTG CTG GAT GTC ACA GCA GCC AGT GAC TGC 1112  
672 Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys  
673 195 200  
674 TGG TTG CTG AAG CGT CAC AAG GAC CTG GGA CTC 1145  
675 Trp Leu Leu Lys Arg His Lys Asp Leu Gly Leu  
676 205 210  
677 CGC CTC TAT GTG GAG ACT GAG GAC GGG CAC AGC 1178  
678 Arg Leu Tyr Val Glu Thr Glu Asp Gly His Ser  
679 215 220  
680 GTG GAT CCT GGC CTG GCC GGC CTG CTG GGT CAA 1211  
681 Val Asp Pro Gly Leu Ala Gly Leu Leu Gly Gln  
682 225 230 235  
683 CGG GCC CCA CGC TCC CAA CAG CCT TTC GTG GTC 1244  
684 Arg Ala Pro Arg Ser Gln Gln Pro Phe Val Val  
685 240 245  
686 ACT TTC TTC AGG GCC AGT CCG AGT CCC ATC CGC 1277  
687 Thr Phe Phe Arg Ala Ser Pro Ser Pro Ile Arg  
688 250 255  
689 ACC CCT CGG GCA GTG AGG CCA CTG AGG AGG AGG 1310

## Patent Application US/07/599,543B

690 Thr Pro Arg Ala Val Arg Pro Leu Arg Arg Arg  
691 260 265  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724 CAG CCG AAG AAA AGC AAC GAG CTG CCG CAG GCC 1343  
725 Gln Pro Lys Lys Ser Asn Glu Leu Pro Gln Ala  
726 270 275  
727 AAC CGA CTC CCA GGG ATC TTT GAT GAC GTC CAC 1376  
728 Asn Arg Leu Pro Gly Ile Phe Asp Asp Val His  
729 280 285 290  
730 GGC TCC CAC GGC CGG CAG GTC TGC CGT CGG CAC 1409  
731 Gly Ser His Gly Arg Gln Val Cys Arg Arg His  
732 295 300  
733 GAG CTC TAC GTC AGC TTC CAG GAC CTC GGC TGG 1442  
734 Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp  
735 305 310  
736 CTG GAC TGG GTC ATC GCT CCC CAA GGC TAC TCG 1475  
737 Leu Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser  
738 315 320  
739 GCC TAT TAC TGT GAG GGG GAG TGC TCC TTC CCA 1508  
740 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser Phe Pro  
741 325 330  
742 CTG GAC TCC TGC ATG AAT GCC ACC AAC CAC GCC 1541

## Patent Application US/07/599,543B

743 Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala  
744 335 340 345  
745 ATC CTG CAG TCC CTG GTG CAC CTG ATG AAG CCA 1574  
746 Ile Leu Gln Ser Leu Val His Leu Met Lys Pro  
747 350 355  
748 AAC GCA GTC CCC AAG GCG TGC TGT GCA CCC ACC 1607  
749 Asn Ala Val Pro Lys Ala Cys Cys Ala Pro Thr  
750 360 365  
751 AAG CTG AGC GCC ACC TCT GTG CTC TAC TAT GAC 1640  
752 Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp  
753 370 375  
754 AGC AGC AAC AAC GTC ATC CTG CGC AAA GCC CGC 1673  
755 Ser Ser Asn Asn Val Ile Leu Arg Lys Ala Arg  
756 380 385  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789 AAC ATG GTG GTC AAG GCC TGC GGC TGC CAC 1703  
790 Asn Met Val Val Lys Ala Cys Gly Cys His  
791 390 395  
792 TGAGTCAGCC CGCCCAGCCC TACTGCAGCA ATTCACTGGC 1743  
793 CGTCGTTTA CAACGTGTGA CTGGGAAAC CCTGGCGTTA 1783  
794 CCCAACTTAA TCGCCTTGCA GCACATCCCC CTTTCGCCAG 1823  
795 CTGGCTAATA GCGAAGAGGC CCCGCACCGA TCGCCCTTCC 1863

796 CAACAGTTGC GCCCCAGTGA ATGGCGAATG GCAAATTGTA 1903  
797 AGCGTTAATA TTTTGTAAATTCGCGTTA AATTTTTT 1941 *See line 495*

## 800 (2) INFORMATION FOR SEQ ID NO:5:

## 801 (i) SEQUENCE CHARACTERISTICS:

802 (A) LENGTH: 98 amino acids

803 (B) TYPE: amino acid

804 (D) TOPOLOGY: linear

805 (ii) MOLECULE TYPE: protein

806 (ix) FEATURE:

807 (D) OTHER INFORMATION: wherein "res."

808 means "residue" and Xaa at res. 2 = (Lys or Arg); Xaa at  
809 res.3 = (Lys or Arg); Xaa res.9 = (Ser or Arg); Xaa at  
810 res.11 = (Arg or Gln); Xaa at res.16 = (Gln or Leu); Xaa  
811 at res. 19 = (Ile or Val); Xaa at res.23 = (Glu or Gln);  
812 Xaa at res.26 = (Ala or Ser); Xaa at res. 34 = (Ala or  
813 or Ser); Xaa at res.38= (Asn or Asp); Xaa at res. 40 =  
814 (Tyr or Cys); Xaa at res.49 = (Val or Leu); Xaa at  
815 res.52= (His or Asn); Xaa at res. 53 = (Phe or  
816 Leu); Xaa at res. 54 = (Ile or Met); Xaa at res. 55 = (Asn  
817 or Lys); Xaa at res. 56 = (Glu, Asp or Asn); Xaa at res.  
818 57=(Thr, Ala or Val); Xaa at res. 61 = (Pro or Ala);  
819 Xaa at res. 67=(gln or Lys); Xaa at res. 69 =  
820 (Asn or Ser); Xaa at 71=(Ile or Thr); Xaa at res.  
821 76= (Phe or Tyr); Xaa at res. 78 = (Asp, Glu or Ser);  
822 Xaa at res. 80= (Ser or Asn); Xaa at res. 84 = (Ile or  
823 Asp); Xaa at res. 85 Arg); Xaa at res. 87 = (Tyr, Ala  
824 or His); and Xaa at res. 93=(Arg or Lys)

## 826 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

828 Cys Xaa Xaa His Glu Leu Tyr Val Xaa Phe  
829 1 5 10  
830 Xaa Asp Leu Gly Trp Xaa Asp Trp Xaa Ile  
831 15 20  
832 Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys  
833 25 30  
834 Glu Gly Cys Xaa Phe Pro Leu Xaa Ser Xaa  
835 35 40  
836 Met Asn Ala Thr Asn His Ala Ile Xaa Thr  
837 45 50  
838 Leu Xaa Xaa Xaa Xaa Xaa Val  
839 55  
840 Pro Lys Xaa Cys Cys Ala Pro Thr Xaa Leu  
841 60 65

842  
843  
844  
845  
846  
847  
848

OK  
JL/P/91  
7/27/91

849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874      Xaa    Ala Xaa    Ser Val Leu Tyr Xaa    Asp  
875                70                                    75  
876      Xaa    Ser Xaa    Asn Val Xaa    Leu Xaa    Lys  
877                80                                    85  
878      Xaa    Pro Asn Met Val Val Xaa    Ala Cys Gly  
879                90                                    95  
880      Cys His  
881  
882  
883 (2) INFORMATION FOR SEQ ID NO:6:  
884 (i) SEQUENCE CHARACTERISTICS:  
885        (A) LENGTH: 437 base pairs  
886        (B) TYPE: nucleic acid  
887        (C) STRANDEDNESS: single  
888        (D) TOPOLOGY: linear  
889 (ii) MOLECULE TYPE: cDNA  
890 (iii) HYPOTHETICAL: no  
891 (iv) ANTI-SENSE: no  
892 (vi) ORIGINAL SOURCE:  
893  
894  
895  
896  
897  
898  
899  
900  
901

Patent Application US/07/599,543B

955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986 CAC TTC ATC AAC CCG GAA ACG GTG CCC AAG CCC 306  
987 His Phe Ile Asn Pro Glu Thr Val Pro Lys Pro  
988 95 100  
989 TGC TGT GCG CCC ACG CAG CTC AAT GCC ATC TCC 339  
990 Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser  
991 105 110  
992 GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC 372  
993 Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile  
994 115 120  
995 CTG AAG AAA TAC AGA AAC ATG GTG GTC CGG GCC 405  
996 Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala  
997 125 130 135  
998 TGT GGC TGC CAC TAGCTCCTCC GAGAATTCAG 437  
999 Cys Gly Cys His  
1000  
1001  
1002 (2) INFORMATION FOR SEQ ID NO:7:  
1003 (i) SEQUENCE CHARACTERISTICS:  
1004 (A) LENGTH: 102 amino acids  
1005 (B) TYPE: amino acid  
1006 (D) TOPOLOGY: linear  
1007 (ii) MOLECULE TYPE: protein

## Patent Application US/07/599,543B

1008 (ix) FEATURE:

1009 (D) OTHER INFORMATION:

1010 wherein each Xaa independently represents one of  
1011 the 20 naturally occurring L-isomer, a-amino acids.

1012

1013 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

1014

1015 Cys Xaa  
1016 1 5 10  
1017 Xaa  
1018 15 20  
1019 Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa  
1020 25 30  
1021 Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa  
1022 35 40  
1023 Xaa  
1024 45 50 55

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys  
1057 60 65  
1058 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1059 70 75  
1060 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

## Patent Application US/07/599,543B

1061                   80                   85  
1062   Xaa Cys  
1063                   90                   95  
1064   Xaa Cys Xaa  
1065                   100  
1066

1067 (2) INFORMATION FOR SEQ ID NO:8:  
1068 (i) SEQUENCE CHARACTERISTICS:  
1069       (A) LENGTH: 97 amino acids  
1070       (B) TYPE: amino acid  
1071       (D) TOPOLOGY: linear  
1072 (ii) MOLECULE TYPE: protein  
1073 (ix) FEATURE:  
1074       (D) OTHER INFORMATION:

1075 wherein each Xaa independently represents one of  
1076 the 20 naturally occurring L-isomer, a-amino acids

1077  
1078 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:  
1079  
1080   Xaa  
1081       1               5                   10  
1082   Xaa  
1083       15              20  
1084   Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa  
1085       25              30  
1086   Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1087       35              40  
1088   Xaa  
1089       45              50                   55

1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113

## Patent Application US/07/599,543B

1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122 Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa  
1123 60 65  
1124 Xaa  
1125 70 75  
1126 Xaa  
1127 80 85  
1128 Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa  
1129 90 95  
1130  
1131  
1132 (2) INFORMATION FOR SEQ ID NO:9:  
1133 (i) SEQUENCE CHARACTERISTICS:  
1134 (A) LENGTH: 136 amino acids  
1135 (B) TYPE: amino acid  
1136 (D) TOPOLOGY: linear  
1137 (ii) MOLECULE TYPE: protein  
1138 (ix) FEATURE:  
1139 (A) NAME: hOP-2P  
1140 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
1141  
1142 Pro Leu Arg Arg Arg Gln  
1143 1 5  
1144 Pro Lys Lys Ser Asn Glu Leu Pro Gln  
1145 10 15  
1146 Ala Asn Arg Leu Pro Gly Ile Phe Asp  
1147 20  
1148 Asp Val Asn Gly Ser His Gly Arg Gln  
1149 25 30  
1150 Val Cys Arg Arg His Glu Leu Tyr Val  
1151 35 40  
1152 Ser Phe Gln Asp Leu Gly Trp Leu Asp  
1153 45 50  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166

1220 Pro Lys Lys Ser Asn Glu Leu Pro Gln  
1221 5 10

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253 Ala Asn Arg Leu Pro Gly Ile Phe Asp  
1254 15 20

1255 Asp Val Asn Gly Ser His Gly Arg Gln  
1256 25 30

1257 Val Cys Arg Arg His Glu Leu Tyr Val  
1258 35

1259 Ser Phe Gln Asp Leu Gly Trp Leu Asp  
1260 40 45

1261 Tyr Val Ile Ala Pro Gln Gly Tyr Ser  
1262 50 55

1263 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser  
1264 60 65

1265 Phe Pro Leu Asp Ser Cys Met Asn Ala  
1266 70 75

1267 Thr Asn His Ala Ile Leu Gln Ser Leu  
1268 80

1269 Val His Leu Met Lys Pro Asn Ala Val  
1270 85 90

1271 Pro Lys Ala Cys Cys Ala Pro Thr Lys  
1272 95 100

1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186 Tyr Val Ile Ala Pro Gln Gly Tyr Ser  
1187 55 60  
1188 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser  
1189 65  
1190 Phe Pro Leu Asp Ser Cys Met Asn Ala  
1191 70 75  
1192 Thr Asn His Ala Ile Leu Gln Ser Leu  
1193 80 85  
1194 Val His Leu Met Lys Pro Asn Ala Val  
1195 90 95  
1196 Pro Lys Ala Cys Cys Ala Pro Thr Lys  
1197 100 105  
1198 Leu Ser Ala Thr Ser Val Leu Tyr Tyr  
1199 110  
1200 Asp Glu Ser Asn Asn Val Ile Leu Arg  
1201 115 120  
1202 Lys Ala Arg Asn Met Val Val Lys Ala  
1203 125 130  
1204 Cys Gly Cys His. *① not valid, please delete*  
1205 135  
1206  
1207  
1208 (2) INFORMATION FOR SEQ ID NO:10:  
1209 (i) SEQUENCE CHARACTERISTICS:  
1210 (A) LENGTH: 133 amino acids  
1211 (B) TYPE: amino acid  
1212 (D) TOPOLOGY: linear  
1213 (ii) MOLECULE TYPE: protein  
1214 (ix) FEATURE:  
1215 (A) NAME: hOP-2R  
1216 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
1217  
1218 Arg Arg Gln  
1219 1

Patent Application US/07/599,543B

1273 Leu Ser Ala Thr Ser Val Leu Tyr Tyr  
1274 105 110  
1275 Asp Glu Ser Asn Asn Val Ile Leu Arg  
1276 115 120  
1277 Lys Ala Arg Asn Met Val Val Lys Ala  
1278 125  
1279 Cys Gly Cys His ~~His~~ *delete*  
1280 130

1281

1282

1283 (2) INFORMATION FOR SEQ ID NO:11:

1284 (i) SEQUENCE CHARACTERISTICS:

1285 (A) LENGTH: 170 amino acids 160  
1286 (B) TYPE: amino acid

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

(D) TOPOLOGY: linear

1318 (ii) MOLECULE TYPE: protein

1319 (ix) FEATURE:

1320 (A) NAME: hOP-2S

1321 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

1322

1323 Ser Gln Gln

1324 1

1325 Pro Phe Val Val Thr Phe Phe Arg Ala

Patent Application US/07/599,543B

1379  
1380  
1381  
1382  
1383  
1384 Leu Ser Ala Thr Ser Val Leu Tyr Tyr  
1385 130 135  
1386 Asp Glu Ser Asn Asn Val Ile Leu Arg  
1387 140 145  
1388 Lys Ala Arg Asn Met Val Val Lys Ala  
1389 150 165  
1390 Cys Gly Cys His 170 160 155  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431

Page: 28

**Raw Sequence Listing**  
**Patent Application US/07/599,543B**

07/08/91  
11:20:47

1432  
1433  
1434

## LINE ERROR

## ORIGINAL TEXT

27 Wrong application Serial Number  
538 Entered and Calc. Seq. Length differ  
811 Response Exceeds Line Limitations  
812 Response Exceeds Line Limitations  
813 Response Exceeds Line Limitations  
814 Response Exceeds Line Limitations  
815 Response Exceeds Line Limitations  
816 Response Exceeds Line Limitations  
817 Response Exceeds Line Limitations  
818 Response Exceeds Line Limitations  
819 Response Exceeds Line Limitations  
820 Response Exceeds Line Limitations  
821 Response Exceeds Line Limitations  
822 Response Exceeds Line Limitations  
823 Response Exceeds Line Limitations  
824 Response Exceeds Line Limitations  
1204 Wrong Amino Acid Designator  
1140 Entered and Calc. Seq. Length differ  
1279 Wrong Amino Acid Designator  
1216 Entered and Calc. Seq. Length differ  
1321 Entered and Calc. Seq. Length differ

OK →(A) APPLICATION NUMBER: US 07/599,543  
see p.15 →(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
at res. 19 = (Ile or Val); Xaa at res. 23  
Xaa at res. 26 = (Ala or Ser); Xaa at res.  
or Ser); Xaa at res. 38= (Asn or Asp); Xa  
(Tyr or Cys); Xaa at res. 49 = (Val or Le  
res.52= (His or Asn); Xaa at res. 53 = (Leu);  
Xaa at res. 54 = (Ile or Met); Xaa  
or Lys); Xaa at res. 56 = (Glu, Asp or A  
57=(Thr, Ala or Val); Xaa at res. 61 = (Xaa  
at res. 67=(gln or Lys); Xaa at res.  
(Asn or Ser); Xaa at 71=(Ile or Thr); Xa  
76= (Phe or Tyr); Xaa at res. 78 = (Asp,  
Xaa at res. 80= (Ser or Asn); Xaa at res.  
Asp); Xaa at res. 85 Arg); Xaa at res. 8  
or His); and Xaa at res. 93=(Arg or Lys)  
Cys Gly Cys His ~~O~~ delete  
Cys Gly Cys His ~~O~~  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

4 line  
limit,  
but o.k.  
here

PAGE: 1

SEQUENCE MISSING ITEM REPORT  
PATENT APPLICATION US/07/599,543B

DATE: 07/08/91  
TIME: 11:20:48

MANDATORY IDENTIFIER THAT WAS NOT FOUND

CLASSIFICATION

PAGE: 1

SEQUENCE CORRECTION REPORT  
PATENT APPLICATION US/07/599,543B

DATE: 07/08/91

TIME: 11:20:48

LINE ORIGINAL TEXT

78 (A) NAME: mOP2 (mature)  
157 (A) NAME: mOP2  
425 (A) NAME: hOP2 (mature)  
537 (A) NAME: hOP2  
924 (A) NAME: OP1  
1139 (A) NAME: hOP-2P  
1215 (A) NAME: hOP-2R  
1320 (A) NAME: hOP-2S

CORRECTED TEXT

(A) NAME/KEY: mOP2 (mature)  
(A) NAME/KEY: mOP2  
(A) NAME/KEY: hOP2 (mature)  
(A) NAME/KEY: hOP2  
(A) NAME/KEY: OP1  
(A) NAME/KEY: hOP-2P  
(A) NAME/KEY: hOP-2R  
(A) NAME/KEY: hOP-2S